These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35209945)

  • 1. Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan.
    Babar ZU
    J Pharm Policy Pract; 2022 Feb; 15(1):9. PubMed ID: 35209945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs).
    Babar ZU
    Res Social Adm Pharm; 2024 Sep; 20(9):934-939. PubMed ID: 38908991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.
    Ocran Mattila P; Ahmad R; Hasan SS; Babar ZU
    Front Public Health; 2021; 9():628744. PubMed ID: 33996712
    [No Abstract]   [Full Text] [Related]  

  • 4. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.
    Nguyen TA; Knight R; Roughead EE; Brooks G; Mant A
    Health Policy Plan; 2015 Mar; 30(2):267-80. PubMed ID: 24425694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.
    Koduah A; Baatiema L; de Chavez AC; Danso-Appiah A; Kretchy IA; Agyepong IA; King N; Ensor T; Mirzoev T
    Syst Rev; 2022 Dec; 11(1):257. PubMed ID: 36457058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
    Babar ZU; Lessing C; Mace C; Bissell K
    Pharmacoeconomics; 2013 Nov; 31(11):1063-82. PubMed ID: 24127259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries.
    Babar ZU; Ramzan S; El-Dahiyat F; Tachmazidis I; Adebisi A; Hasan SS
    Front Pharmacol; 2019; 10():1375. PubMed ID: 31824316
    [No Abstract]   [Full Text] [Related]  

  • 10. Systematic reviews of ten pharmaceutical pricing policies - a research protocol.
    Tordrup D; van den Ham HA; Glanville J; Mantel-Teeuwisse AK
    J Pharm Policy Pract; 2020; 13():22. PubMed ID: 32695425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
    Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
    PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How does external reference pricing work in developing countries: evidence from Iran.
    Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
    Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
    [No Abstract]   [Full Text] [Related]  

  • 14. Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?
    Srivastava D; McGuire A
    BMC Public Health; 2014 Jul; 14():767. PubMed ID: 25073407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of National Drug Pricing Policy 2018 on access to medicines in Lahore division, Pakistan: a pre-post survey study using WHO/HAI methodology.
    Saeed A; Saeed H; Saleem Z; Yang C; Jiang M; Zhao M; Ji W; Aziz MM; Khan FU; Gillani AH; Atif N; Fang Y; Babar ZUD
    BMJ Open; 2020 Oct; 10(10):e034720. PubMed ID: 33033079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in external reference pricing implementation: does it matter for public policy?
    Gill J; Fontrier AM; Kyriopoulos D; Kanavos P
    Eur J Health Econ; 2019 Dec; 20(9):1375-1397. PubMed ID: 31444673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Access to essential medicines in Pakistan: policy and health systems research concerns.
    Zaidi S; Bigdeli M; Aleem N; Rashidian A
    PLoS One; 2013; 8(5):e63515. PubMed ID: 23717442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010.
    Kaplan WA; Ritz LS; Vitello M; Wirtz VJ
    Health Policy; 2012 Aug; 106(3):211-24. PubMed ID: 22694970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
    Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
    Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.